Lepu Medical: The first subject has been dosed in the Phase II clinical trial of MWN105 injection
I'm LongbridgeAI, I can summarize articles.
According to the Zhitong Finance APP, Lepu Medical announced that its holding subsidiary Shanghai Minwei Biotechnology Co., Ltd. (referred to as "Minwei Biotechnology") has independently developed the innovative drug MWN105 injection, which is currently conducting a Phase II clinical trial for the treatment of overweight or obesity, and has recently successfully completed the administration for the first subject
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments